New Mathematical Theorem Proves Children's Drug Doses Can Be Calculated With Certainty

Researcher publishes framework showing pediatric dosing errors are a solvable math problem, not an unavoidable medical reality ---
By: Universal Standard Axiom Corporation
 
LOS ANGELES - May 10, 2026 - PRLog -- Primarch Michael A. Russell of the Universal Standard Axiom Corporation has introduced a new mathematical framework designed to revolutionize pediatric pharmacology.

His proposal suggests that children's drug dosages, which are traditionally provided as probabilistic ranges (such as 10 to 15 mg/kg), can instead be calculated as exact, verifiable values.

The Pediatric Constitutional Dosing Theorem, submitted to Academic Pediatrics, proves that for every child whose biological parameters are fully specified, one unique correct dose exists and is mathematically derivable.

"The therapeutic range is not a fact of biology," Russell states. "It is the mathematical record of every biological variable we chose not to measure. When we measure everything relevant, the range collapses to a number."

BACKGROUND

Dosing errors are among the most common preventable adverse events in pediatric medicine, occurring in an estimated 5 to 15 percent of hospital admissions involving children. Over 93 percent of drugs prescribed to children lack child-specific dosing data, forcing clinicians to rely on weight-based extrapolations from adult studies.

THE FRAMEWORK

The theorem introduces a seven-parameter biological vector — body composition, developmental stage, pharmacogenomic profile, microbiome state, circadian phase, comorbidity interactions, and real-time physiological state — and proves mathematically that dosing error decreases monotonically as each parameter is incorporated. When all parameters are measured, dosing error reaches zero.

Current standard of care typically incorporates only two of the seven parameters: weight and age.

The paper also formalizes the Pediatric Harm Amplification Principle — that dosing errors in children carry consequences far greater than equivalent errors in adults, due to developmental window irreversibility and lifetime impact.

A structured seven-pass refinement protocol is provided for clinical implementation, along with seven specific empirical predictions and a full research agenda for prospective validation.

AVAILABILITY

The full manuscript (MARUSC-2026-PCDT-AP-001) has been submitted to Academic Pediatrics. All framework materials are released to the public domain under CC0 1.0 Universal for non-commercial academic use.

ABOUT ADVANCEER IVS LABS

Advanceer IVS Labs is the research division of Universal Standard Axiom Corporation, directed by Primarch Michael A. Russell, USPTO Category Creator in Operational Superintelligence and Machine Consciousness.

Contact: Michael@advanceerivs.com

Contact
Michael A. Russell
***@normativek.com
End
Source:Universal Standard Axiom Corporation
Email:***@normativek.com Email Verified
Tags:Pediatric
Industry:Health
Location:Los Angeles - California - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Page Updated Last on: May 10, 2026
Advanceer IVS News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share